By Puyaan Singh Sept 19 (Reuters) - Regeneron said on Friday its experimental therapy showed either a complete or partial disappearance of a precancerous disorder, which manifests into blood cancer, in all patients in a mid-stage trial. The bispecific antibody therapy, Lynozyfic, showed a 100% overall response rate in a study with 24 patients with high-risk smoldering multiple myeloma. The...

The European Medicines Agency’s (EMA) human medicines committee (CHMP) has recommended extending the therapeutic indication of Amgen Inc.’s Uplizna (inebilizumab) to include the treatment of adult patients with active immunoglobulin G4-related disease (IgG4-RD). IgG4-RD is a rare, chronic, autoimmune condition (a disease caused by the body’s own defence system attacking normal tissue) that can cause fibrosis (tissue scarring) and inflammation in...

01:16 PM EDT, 09/19/2025 (MT Newswires) -- (Updates with recent share movement in the first and second paragraphs.) Platinum Analytics Cayman (PLTS) shares were up more than 46% in recent trading after the company's stock made its debut on Nasdaq earlier Friday following an initial public offering of 2 million shares that were priced at $4 each for $8 million...

01:17 PM EDT, 09/19/2025 (MT Newswires) -- Red Cat Holdings ( RCAT ) said Friday that it has closed an underwritten public offering of about 18 million common shares, which includes 2.34 million shares from the underwriters' option, for gross proceeds of $172.5 million. The company intends to use the proceeds for general corporate purposes and working capital, including funding...